Cellectis to cut 70% of staff as it abandons CAR-T for in vivo gene editing
Paris-based Cellectis is eliminating up to 70% of its workforce as it pivots from allogeneic CAR-T cell therapies to in vivo gene editing. The company scrapped its clinical-stage lasme-cel and eti-cel programs in September 2026, citing a changed commercial landscape. It is now focusing on two preclinical candidates: HEAL-101 for severe hypertriglyceridemia and HEAL-201 for severe hypercholesterolemia. Third-quarter financial results show a net loss of $101.1 million for the nine-month period, with cash reserves expected to fund operations into late 2028.
